Recently, a multicenter Italian study [52] demonstrated, in children 6–17 years old with severe asthma, an association between the baseline urinary metabolomic profile and the clinical response to the anti-IgE monoclonal antibodies omalizumab, paving the way for the possible prediction of the patients more likely to benefit from this treatment. Here, IGHE is linked to asthma.